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1. Introduction 
Transgenic animal technology is one of the fastest growing biotechnology areas. It is used to 
integrate exogenous genes into the animal genome by genetic engineering technology so 
that these genes can be expressed and inherited by offspring. The transgenic efficiency and 
precise control of gene expression are the key limiting factors in the production of transgenic 
animals. A variety of transgenic techniques are available, each of which has its own 
advantages and disadvantages and needs further study because of unresolved technical and 
safety issues. Further studies will allow transgenic technology to explore gene function, 
animal genetic improvement, bioreactors, animal disease models, and organ transplantation. 
This article reviews the recent developments in animal gene transfer techniques, including 
microinjection method, sperm vector method, Embryonic stem cell, somatic cell nuclear 
transplantation method, retroviral vector method, germ line stem cell mediated method to 
improve efficiency, gene targeting to improve accuracy, RNA interference-mediated gene 
silencing technology, zinc-finger nucleases–gene targeting technique and induced 
pluripotent stem cell technology. These new transgenic techniques can provide a better 
platform to develop transgenic animals for breeding new animal varieties, and promote the 
development of medical sciences, livestock production, and other fields. 
2. Microinjection  
In the past 20 years, DNA microinjection has become the most widely applied method for 
gene transfer in animals. The mouse was the first animal to undergo successful gene transfer 
using DNA microinjection. This method involves: 1) transfer of a desired gene construct (of 
a single gene or a combination of genes that are recombined and then cloned) from another 
member of the same species or from a different species into the pronucleus of a reproductive 
cell; 2) in vitro culture of the manipulated cells to develop to a specific embryonic phase; and 
3) then transfer of the embryonic cells to the recipient female. 
Microinjection equipments include microscopes and micromanipulators. Various 
microscope configurations from upright to inverted styles made by different companies (e.g. 
Leica, Zeiss, Nikon, Olympus) afford excellent differential interference contrast. 
Micromanipulator systems are grouped into either air-driven systems (e.g. Nikon, Zeiss, 
Eppendorf) or oil-driven hydraulic systems. Microinjection needles and slides are also 
needed during experiment. 
www.intechopen.com
 
Polymerase Chain Reaction 
 
256 
Steps for getting transgene production and evaluation from DNA microinjection are: 
collection of fertilized eggs from superovulated donors, injection of interested genes into 
male pronuclei, surgical transfer of 20-25 eggs into oviduct of pseudopregnant recipients 
that carry eggs to term, and PCR or southern blot analyses to detect offspring carrying the 
transgenes. 
Transgenic frequencies obtained from pronuclear microinjection are about 5%-30%. Some 
factors influence transgenesis production. The studies in mouse done by Brinster et al. (1985) 
showed that: 1) linear DNA fragments integrated with greater efficiency than circular or 
supercoiled DNA; 2) transgene DNA should be injected in low amounts othervise it had 
toxic effects on the embryos; 3) nuclear injection was dramatically more efficient than 
cytoplasmic injection. In general, good results may be obtained with equipment systems, 
injector’s experience and skills, and the technique. A major advantage of this method is its 
applicability to a wide variety of species. 
3. Sperm-mediated gene transfer  
The finding that mature spermatozoa act as vectors of genetic materials, not only for their 
own genome, but also for exogenous DNA molecules, has suggested a strategy for animal 
transgenesis alternative to DNA microinjection. Exploiting this possibility, protocols for 
sperm-mediated gene transfer (SMGT) have been developed in a variety of animal species 
with extremely variable results.  
In 1989 Lavitrano et al. described a simple and efficient technique, sperm-mediated gene 
transfer to produce transgenic mice. In this technique, DNA was mixed with sperm cells 
before in vitro. 30% of offspring mouse were integrated foreign DNA. In subsequent years, 
however, many successful reports of SMGT have been published. 
The basic principle of sperm-mediated gene transfer is quite straightforward: seminal 
plasma-free sperm cells are suspended in the appropriate medium, and then incubated with 
DNA. The resultant DNA-carrying sperms are then used to fertilize eggs, via in vitro 
fertilization or artificial insemination or, in the case of aquatic animals, via waterborne 
(natural) fertilization. To improve transgenic efficiency, ‘augmentation’ techniques such as 
electroporation or liposomes to ‘force’ sperm to capture transgenes were used in some studies. 
Here we briefly introduced methods of SMGT. 1) Sperm cells directly incubated with 
exogenous DNA. Lavitrano et al. (1989) first incubated mouse sperms with DNA to 
integrate foreign genes into the germ cells and produce transgenic mice. But as low 
efficiency of the method, now researchers use this method in combination with other 
methods of sperm carrier techniques to obtain transgenes. 2) Transfection of DNA into the 
sperm cells mediated by liposomes. These cationic lipids interact with the negatively 
charged nucleic acid molecules forming complexes that the nucleic acid is coated by the 
lipids. The positive outer surface of the complex can then associate with the negatively 
charged cell membrane, allowing the internalization of the nucleic acid. 3) Electroporation-
mediated import of foreign DNA into sperms. High voltage electric field can induce a 
temporary reversible membrane permeability changes, which allowes the foreign DNA into 
the cells more easily. Studies showed that this method can improve the transgenic efficiency 
up to 22% of the embryos in pigs, cattle, chickens and other animals. However, sperm cells 
underwent electroporation have two aspects. On one hand, some channels temporarily 
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opened on cell membranes are conducive to the entry of foreign gene; on the other hand, the 
shock is also an injury to cells that causes irreversible damage to sperm motility. 4) 
Adenoviral vector mediated gene transfer. Farre et al. (1999) tested the ability of adenoviral 
vectors to transfer DNA into boar spermatozoa and to offspring. Exposure of spermatozoa 
to adenovirus bearing the E. coli lacZ gene resulted in the transfer of the gene to the head of 
the spermatozoa. Of the 2-to 8-cell embryos obtained after in vitro fertilization with 
adenovirus-exposed sperm, 21.7% expressed the LacZ product. Four out of 56 piglets (about 
7%) obtained foreign gene in PCR analyses after artificial insemination with adenovirus-
exposed spermatozoa. SMGT is based on the intrinsic ability of sperm cells to bind and 
internalise exogenous DNA and to transfer it into the egg at fertilisation as illustrated in Fig. 1. 
 
Fig. 1. Sperm-mediated gene transfer in the pig. 
Mechanisms of nucleic acid uptaken by sperm are not known very well. It is suggested that 
the interaction of exogenous molecules may trigger an endogenous reverse transcriptase 
(RT) activity in spermatozoa. Such RT activity is able to reverse transcribe exogenous RNA 
molecules (specifically, the human poliovirus RNA genome was used in the study that 
provided the first set of evidence) into cDNA, which are transferred to embryos following in 
vitro fertiliszation (Giordano et al., 2000). That finding suggested for the first time that a 
sperm endogenous RT is implicated in the generation of newly reverse-transcribed 
sequences and, more generally, established the notion that the retrotransposon/ retroviral 
machinery is involved in SMGT. 
Now it is well established that spermatozoa can play a role in transgenesis in all species. 
Their ability to take up exogenous DNA molecules can be exploited to transmit novel 
genetic information to the offspring after fertilization. This potential is highlighted by the 
recent development of SMGT variant protocols. 
4. Embryonic stem cell-mediated gene transfer 
This method involves isolation of totipotent stem cells, which are undifferentiated cells that 
have the potential to differentiate into any type of cells (somatic and germ cells) and 
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therefore to give rise to a complete organism. Then the desired DNA sequences are inserts 
into the genome of embryonic stem (ES) cells cultured in vitro by homologous 
recombination. The cells containing the desired DNA are incorporated into the host’s 
embryo, resulting in a chimeric animal. This technique is of particular importance for the 
study of the genetic control of developmental processes and works well in mice.  
It has the advantage of allowing precise targeting of defined mutations in the gene via 
homologous recombination. Based on the resultant function of the targeted gene, gene 
targeting methods have opened two lines of investigation: the gene knock-out (KO) to 
disrupt the existing gene, and the gene knock-in (KI) to insert a functional new gene. 
Stem cells of the embryo can be classified into three types: embryonal carcinoma (EC) cells, 
embryonic stem (ES) cells, and primordial germ cells or embryonic germ (PGCs) cells. EC 
cells are derived from the stem cells of teratocarcinomas; ES cells are derived from the inner 
cell mass of blastocysts; and PGCs are derived from the posterior third of the embryo. Here, 
we focus on ES cells, which are undifferentiated, pluripotent and usually are expected to 
have the capacity to produce both gametes and all somatic-cell lineages. Up to now, two 
methods of producing transgenic mice are widely used (Figure 2). 
 
Fig. 2. Two methods of producing transgenic mice are widely used. Method 1, transforming 
embryonic stem cells (ES cells) growing in tissue culture with the desired DNA; Method 2, 
injecting the desired gene into the pronucleus of a fertilized mouse egg. 
4.1 Establishment of ES cells 
ES cells were first established by two laboratories independently in 1981 (Evans and 
Kaufman, 1981; Martin, 1981). They changed hormone levels, blastocyst was cultured to 
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obtain delay in its development. 4 to 6-day blastocyst inner cell mass (ICM) was separated, 
then co-cultured on the mitomycin C-treated Unlimited lines of fibroblasts (STO) feeder 
layer (Feeder). After cell proliferation and inhibition of differentiation of passage, the first 
mouse undifferentiated ES cell lines were established. It was shown that mouse ES cells by 
blastocyst injection could widely induce variety of organizations involved in the formation 
of chimeric animals at rate of 61%. 
Currently, mouse fibroblasts unlimited line (STO) or mouse embryonic fibroblasts (Mouse 
Embryonic Fibroblast, namely MEF) was widely used to prepare the feeder layer. These cells 
can secrete fibroblast growth factor (FGF), differentiation inhibitory factor (DIA), white 
leukemia inhibitory factor (LIF) and other substances. They also promote the growth and 
colonization of ES cells and suppress their differentiation. The STO or MEF is treated with 
mitomycin vitamin C or other mitotic inhibitor, early embryos or PGCs is cultured on the 
feeder layer and ES cells can be obtained. Rat liver cell conditioned medium (buffalo liver 
conditioned medium) is another wildly used differentiation inhibiting medium. In addition, 
sheep oviduct epithelial (oTE), goat oviduct epithelial (cTE), sheep uterine epithelium (oUE), 
goat uterine epithelium (cUE), bovine granulosa cells (bG), bovine uterine fibroblasts (bUF) 
and fetal bovine testes, kidney and liver fibroblasts (fbTF, fbKF, fbLF), etc., are also used as 
feeder layers in laboratories.  
Several conditions must be met for isolating ES cells. 1) Present cells in culture must be 
undifferentiated and pluripotent. 2) The pluripotent cells must be deprived of 
differentiation signals in culture. 3) The cells must be stimulated, or at least be allowed, to 
proliferate. 
4.2 Characteristics of ES cells  
ES cells are small, aggregated and unpolarized cells forming islands on the feeder layers and 
have large nucleoli and a high nucleo-cytoplasmic rate. Cell markers have been used to 
characterize undifferentiated or differentiated ES cells. Alkaline phosphatase is equivalent to 
the cell surface nonspecific alkaline phosphatase of the inner cell mass of the mouse 
blastocyst. Other markers are surface glycolipids (ECMA-7), embryoglycans (SSEA-1) and 
so on. 
As gene expression characteristics of ES cells, they express all the “house-keeping” genes 
involved in the machinery of cell cycling and some receptors to factors which allow them 
escaping cycling and differentiating. 
4.3 ES cells for transgenesis 
ES cells are highly efficient materials for animal cloning. With the development of chimeric 
nuclear transfer technology and production technology, ES cells are widely used in animal 
cloning. Proliferation of ES cells derived from donor as the nucleus, which in chimeric 
germline, produce following generations by sperm or egg cell proliferation. 
Introduction of foreign DNA by electroporation into ES cells is very efficient. The DNA 
integrates into genome at a frequency of -10-3, then numerous markers are used for efficient 
selection. The gene-modified cell clones are introduced back into preimplantation stage 
embryos, either by blastocyst injection or by morula aggregation, to produce chimeras. 
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There are two main methods of embryonic stem cell-mediated gene transfer: one is gene 
trap, another is gene targeting. We will discuss in the following section. 
5. Somatic cell nuclear transfer 
ESCs are totipotent in development, capable of limitless passage and proliferation, and have 
become the ideal cells for gene targeting. However, in many species, especially the large 
agricultural animals, ESCs have not been successfully isolated or cultured. For these 
animals, somatic cells are easily obtained in large numbers and can be cultured in vitro. 
Somatic cell nuclear transfer (SCNT) is a technique for cloning. The nucleus is removed from 
a healthy egg. The enucleated egg becomes the host for a nucleus that is transplanted from 
another cell, such as a skin cell. The resulting embryo can be used to generate embryonic 
stem cells with a genetic match to the nucleus donor (therapeutic cloning), or can be 
implanted into a surrogate mother to create a cloned individual, such as Dolly the sheep 
(reproductive cloning) (Figure 3). 
 
Fig. 3. Diagram of the nuclear transfer procedure that produced the dolly sheep. 
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Cloning by nuclear transfer from adult somatic cells is a remarkable demonstration of 
developmental plasticity. When a nucleus is placed in oocyte cytoplasm, the changes in 
chromatin structure that govern differentiation can be reversed, and the changed nucleus 
can control the development of oocyte to term. 
Dolly was cloned by SCNT with a nucleus from a cultured mammary gland cell. In the 
Edinburgh experiment, three types of cells were used as karyoplasts: (i) mammary 
epithelium, (ii) fetal fibroblasts, and (iii) embryo-derived cells. The efficiencies of fusion 
were relatively high for all three cell types, which were 63.8%, 84.7% and 82.8% respectively. 
5.1 The main methods of nuclear transfer 
According to the different donor cells, somatic cell nuclear transfer divided into early 
embryo nuclear transplantation, nuclear transfer and differentiated embryonic stem cell 
nuclear transfer. From the present point of view, there are two somatic cell nuclear transfer 
technology: one is Roslin technology, another is Honolulu technique. Compared with 
previous techniques, the major breakthrough of Roslin method is the use of blood starvation 
method, which enables the proliferation of cultured cells temporarily in the G0 phase week. 
To ensure that the donor nucleus and development of the cytoplasm of recipient cells 
synchronized, electric pulse method was used. The fusion and activation of donor nucleus 
and enucleated oocyte were triggered by oocyte. 
In Honolulu technique, a slight modification was made in the direct use of G0 phase or G1 
phase of somatic cell nuclear as donor to avoid serum starvation. Donor nucleus was 
transferred into the oocyte cytoplasm and stayed for some time (6h). Then the oocyte was 
activated and stimulated to proliferation with strontium ions (chemical activation). More 
details of nuclear transplantation technology include the following steps: 
5.1.1 Choose of recipient cells and the nuclear removing 
MII oocytes are the most use of nuclear transplantation donor, but different laboratories 
used different activation time: before the activation of nuclear transfer, nuclear transfer 
when activated, delayed activation of nuclear transfer, and so on. No matter which methods 
using the blastomeres of early embryos, ES cells or somatic cell, nuclear transfer ported to 
this type of recipient, all get the offspring. 
Nuclear removing from oocytes are mainly done by mechanical and chemical methods. 
Earlier mechanical method is the use of glass needle under the microscope, including the 
blind absorption and fluorescence dye staining under UV to remove nuclear. In 1998, 
Wakayama et al. first applied piezoelectric microinjection (PEM) to remove nuclear. Because 
of its high frequency of vibration control, more easily through the zona pellucida, and the 
small damage to the fertilized egg, the success rate to get transgenes was greatly improved. 
Compared with the mechanical method, chemical method is much simpler and easier to 
remove nuclear. In the early time, researchers mainly used early etopside (ethylene grapes 
pyran sugar) and cycloheximide treatment. However, the success rate was low. Recently 
Gasparrini et al. (2003) chose the decarboxylation youthful acid base to successfully remove 
the nucleus from the mouse oocyte. But whether this method is applicable to other species 
needs to further experiments. 
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5.1.2 The choice of donor cells and transplantation 
Currently cells mainly used in the nuclear donor are: cumulus cells, testicular pillar cells, 
sperm cells, brain cells, fetal or adult fibroblasts, breast cells, embryonic stem cells (ES cells) 
and so on. The synchronization of donor and recipient cell cycle is an important factor 
affecting the development of nuclear transfer. Early studies suggest that donor cells in the 
G0 is essential to the success of somatic cell nuclear transplantation, and that cells in the G0 
phase can be selected or artificially induced. However, the recent discovery indicated that 
the nuclear transfer from donor cells in G1 or G2 or M phase was also a success way. 
Meanwhile, the study also found that in mice, somatic cell nuclear transfer had a greater 
efficiency of transplantation. 
There are two ways to transplant donor nuclei: fusion and injection. Fusion includes the 
chemical fusion, sendai virus mediated fusion and electro-fusion. And injection includes 
glass needle injection and piezoelectric microinjection. 
5.1.3 Oocyte activation 
Mature oocytes as recipients are lack of nuclear migration and the fertilization, so  they must 
be manually activated to promote their further development. The activation methods are 
currently mostly used with electrical activation, ethanol, ionomycin, calcium ionophore 
A23187, chlorine strontium, 3-phosphatidylinositol (IP3), sperm extract and so on. These 
methods are often used in combination or with protein synthesis inhibitors (actinomycetes 
ketone, puromycin), serine threonine protein kinase inhibitor DMAP. However, studies 
have found that all of these methods can only lead to increased concentration of intracellular 
calcium in oocytes, and calcium can not form vibration, which might be the reason of low 
efficiency of nuclear transfer. 
5.2 Application of SCNT 
This technology will be helpful in understanding the most important issues such as nuclear 
matter interaction, the nucleus division and reprogramming, changes in mitochondria of 
reconstructed embryos, cell aging. Nuclear transfer technology also provides a powerful 
tool to wildlife, endangered species’ protection. 
In agricultural area, this technology will further enrich the quality of breedings. Nuclear 
transfer technology can be used to accelerate the breeding process and expand population 
within the effective number in a short time. Both nuclear transfer and gene targeting can be 
used to modify target genes and produce new varieties with superior traits (such as 
increased fecundity, increased milk yield, strengthen resistance to disease, etc.). 
In the medical field, SCNT was used to clone tissues and organs for patient transplant, such 
as the treatment of Parkinson's disease, etc. Meanwhile, the combination of gene targeting 
and nuclear transfer technology established various animal models of human disease for 
medical and pharmaceutical research. 
But lots of questions of nuclear transplantation in mammals are still not well solved, 
including cytoplast aging, cytoplast cell-cycle stage, activation procedure, source of 
karyoplasts and its differentiation, karyoplast cell cycle stage, serial transfer, karyoplast: 
cytoplast (nucleocytoplasmic interactions), species specific differences. Instead, we have 
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aimed at highlighting some of the unanswered questions relating to somatic cell cloning that 
will require resolution before the procedure becomes useful for practical purposes. 
6. Retrovirus-mediated gene transfer 
A retrovirus is a virus that carries its genetic material in the form of RNA rather than DNA. 
In this method, retroviruses are used as vectors to transfer genetic material into the host cell, 
resulting in a chimera, an organism consisting of tissues or parts of diverse genetic 
constitution. Chimeras are inbred for as many as 20 generations until homozygous (carrying 
the desired transgene in every cell) transgenic offspring are born. 
Retrovirus-mediated expression cloning was developed in mid 1990s. The most important 
features of retrovirus as vectors are the technical ease and effectiveness of gene transfer and 
target cells specificity. When cells are infected by retroviruses, the resultant viral DNA, after 
reverse transcription and integration, becomes a part of the host cell genome to be 
maintained for the life of the host cell (Ponder, 2001). It is also reported that DNase 
hypersensitive regions are the preferred targets for retrovirus integration. Unlike DNA 
microinjection, integration of a viral gene does not seem to induce rearrangements of the 
host genome, except for a short duplication at the site of integration (Jaenisch, 1988).  
6.1 Retrovirus biology and Retroviral vector design 
Retroviruses are animal viruses contain two positive-strand RNA genomes. The word 
“retro” means, when the virus vectors infect a host cell, the viral RNA is reverse transcribed 
in the cytoplasm making linear double-stranded DNA. This dsDNA then is transported into 
host cell mucleus and integrates into a chromosome directly with no change of its original 
linear form.  
The retrovirus genome can be divided into trans- and cis- acting sequences. Trans-acting 
protein-coding genes are gas, pol and env. The gas gene encodes the structural components of 
the virus. The pol gene encodes the RNA-dependent DNA polymerase (reverse-
transcriptase), integrase for the integration of reverse-transcribed viral DNA into the host 
cell chromosome, and the protease for posttranslational cleavage of viral proteins. The env 
gene encodes the surface envelope glycoproteins.  
Cis region are located at the 5’ and 3’ ends of the genome. 1) The long terminal repeat (LTR) 
contains transcription and integration signals. 2) Primer binding site and polypurine 
sequence are for reverse transcription. 3) Posttranscriptional splicing sites include splicing 
donor and acceptor sites along with two short fragments within the viral intron for env 
mRNA production. 4) E signal is for encapsidation of murine leukemia virus (MLV) and 
reticuloendotheliosis virus (REV), respectively. 
The viral vector based on Moloney murine leukemia virus (Mo-MLV) is the most widely 
used retroviral vector systems. Mo-MLV retroviral vector system is constructed based on the 
Mo-MLV genes for packaging, reverse transcription and integration of the required cis-
acting elements and trans-acting protein coding sequence of separation, respectively, as well 
as recombinant retroviral vector elements and packaging cell line. In the molecule level of 
recombinant retroviral vector, the foreign gene replace the original virus structural protein 
coding region, but essential components, the virus replication, transcription and packaging 
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sequences are preserved. Retrovirus structural protein coding genes are provided in trans 
from the packaging cells. Target cells are infected with this virus particles, so that the target 
gene stably integrated in the genome or chromosomes of target cells, in order to achieve the 
transfer of foreign genes. 
6.2 Packing cell lines 
Packing cells are designed to synthetize all retroviral proteins necessary for the production 
infectious particles. The purpose of a packing cell is to provide Gag, Pol, and Env protein to 
the retroviral vectors having no trans-acting sequences. NIH3T3 cells transformed with 
appropriate MLV genes are the most popular system for gene transfer in mammalian cells. 
In earlier packaging cell construction, NIH3T3 cells were transfected with the gag, pol, and 
env genes of MLV in a single transcriptional unit, causing production of replication-
competent helper virus. In the later work, decreased the possibility of homologous 
recombination were made. For instance, in ampli-GPE packaging cells, the 5’ LTR promoter 
replaced with mouse metallothionein promoter in controlling of the gag, pol, and env genes. 
Then the PG13 packing cell line, the BOSC23 packing cell line, and the 293GP/VSV-G 
packing cell line, have the advantage of low replication competent virus production, high 
DNA transfection efficiency and wide host cell ranges. 
Retroviral vectors have been mainly used in somatic transgenesis for gene expression 
studies by using reporter genes, cell lineage, and for antisense sequences inhibition of gene 
expression in specific cell types. 
6.3 Problems of retroviral vectors in gene transfer 
The maximum size for reverse transcription of each vector is about 10kb, which may affect 
the expression level in transgenic animals. Another problem is the recombination, which is 
production of replication competent retrovirus from virus-producing cells. So nowdays, 
reducing the homologous sequences between DNAs for packing cells and vector and by 
using different plasmids to separate different genes gets over this problem. 
7. Germ line stem cell technique 
7.1 Spermatogonial stem cell technique 
Spermatogonial stem cells (SSCs) are a population of cells in mammalian testes that have 
high potential to self-renew and differentiate similarly to embryonic stem cells. SSCs 
transplantation is a recently developed animal reproduction technique that involves the 
injection of in vitro cultured spermatogonial stem cells from an age-matched male donor into 
the seminiferous tubule of age-matched host animal to produce germ cells. During the in 
vitro culture of spermatogonial stem cells, positive spermatogonial stem cells that will be 
transferred can be screened and, thus, the transgenic efficacy can be significantly enhanced. 
7.1.1 Origin of spermatogonial stem cells 
Spermatogonial stem cells derive from the birth of the original sex cells, the original sex cells 
are from primordial germ cells (primordial germ cells, PGCs). PGCs are generated in early 
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embryo development in mammals, processing in earlier period independent of other cell 
lines on a small group of cells. They have been integrated into the base from the yolk sac 
formed after the intestine. After along intestinal active migration, and migration on the way 
to proliferate in pregnancy 10.5 d, PGCS eventually arrives at the genital ridge to form a 
gonad. PGCs then differentiate and form germ cell precursor cells known as the the original 
sex cells. In the male animals, the original cells of strong mitotic activity are not stationary 
for a long time, until the animal was born. In mice, spermatogonial stem cells appear in the 
course of 6 d after birth, the earliest spermatogonial stem cells appeared probably after birth 
3-4 d. The specific time for the original cell into spermatogonial stem cells in other species is 
unclear. Livestock may take a few months, and spiritual may take about a few years. Some 
studies have shown that there are two types of primary cells in neonatal mouse testis, one 
directly differentiates into spermatogonia and completes the first form of spermatogenesis, 
and another form of spermatogonial stem cells, in the later time provides the basis for 
spermatogenesis.  
7.1.2 Spermatogonial stem cell proliferation and differentiation 
Spermatogonial stem cells are located in the testis seminiferous tubule basement membrane, 
and are round, less cytoplasm. Their nucleus were round or slightly oval, often dominant 
with chromatin, little heterochromatin. They have abundant of cytoplasmic ribosomal cores, 
mitochondria. Based on cell arrangement characteristics, mice type A spermatogonia can be 
divided into three types: A single spermatogonia (As); A paired spermatogonia (Apr); and 8, 
16 or 32 cells of A aligned spermatogonia (Aal). As having stem cell activity, As, Apr, Aal 
are referred as undifferentiated spermatogonia. After division, daughter cells of As separate 
from each other as two new As stem cells, or due to incomplete cytokinesis, two daughter 
cells form Apr by cytoplasmic bridges between connected to each other. Under normal 
circumstances, about half of the As cell divides and forms Apr cells, while the other half 
through the proliferation renews themselves and keeps the number of stem cells. Apr cells, 
by four further division, form 8, 16 or 32 cells Aal-based original cells, which then divide 
into the Al type A spermatogonia. After over six consecutive division, Al type A 
spermatogonia differentiate into type A2 spermatogonia, which in turn gradually 
differentiate from the A2 → A3 → A4 → In → B, and finally into B Type A spermatogonia. 
Proliferation and differentiation of stem cells generally are subject to balance to their 
microenvironment (niche) of the regulation. Current study suggests that, spermatogonial 
stem cell micro-environment is seminiferous tubules and interstitial blood vessels around 
the area. As /Apr / Aal tends to distribution there, and will move out of this area when 
they differentiate into A1 spermatogonial cells. 
GDNF from supporting (Sertoli) cells is one of the most important cytokines regulating 
spermatogonial stem cell proliferation. Studies have shown that over-expression GDNF 
expression in mice leads to accumulate undifferentiated spermatogonia. When the GDNF-/+ 
mouse spermatogonial stem cells is exhausted, the process of spermatogenesis is damaged. 
More importantly, GDNF has become a necessary factor for culturing spermatogonial stem 
cells. GDNF binds to GFRA1, induces activation of RET, and then recruits other molecules to 
the RET intracellular domain. The recent study showed that BCL6 and Etv5 genes were 
regulated by GDNF. BCL6 and Etv5 knockout mice are showing spermatogenesis and sertoli 
cell degeneration syndrome phenotype. In addition, genetic models in mice also observed 
that two non GDNF regulated genes: Plzf and Taf4b, play an important role in maintaining 
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the proliferation of spermatogonial stem cells in body. Plzf knockout mice with aging, 
accompanied by the original cell degeneration, and gradually lose the structure of the 
seminiferous tubule. And Plzf - / - mouse spermatogonial cell transplantation can not be re-
formed seminiferous epithelium. Taf4b knockout mice become sterile at 3 months, also 
appear cell syndrome phenotype. 
There are three important regulatory points in the differentiation of spermatogonial cells: 1) 
the change between As and Apr; 2) Aal changes to the A1 and A1 to B spermatogonial cell 
transformation; 3) Apr spermatogonia without completing cytokinesis. The cytoplasmic 
bridge connecting two daughter cells is considered to be first visible sign of spermatogonia 
differentiation. However, little is known about how to control differentiation of 
spermatogonia process. Current studies showed that Vitamin A (RA), c-Kit and other genes 
in the germ cell differentiation play an important role. If RA defects, only undifferentiated 
testicular spermatogonia exist, when RA renew, Aal spermatogonia after block of re-entered 
the cell cycle differentiate into A1 spermatogonia. RA can induce cultured undifferentiated 
spermatogonia to express large amount of Stra8 and c-Kit, and these two genes are 
considered as the molecular markers for spermatogonial stem cells starting to differentiate. 
C-kit oncogene is the original W locus, encoding the tyrosine kinase receptor and its ligand 
is stem cell factor (SCF). C-kit point mutation in male mice results in the initial stage of 
spermatogenesis DNA synthesis disorder, no DNA synthesis in the process of Aal to A1 
differentiation, and complete infertility. 
7.1.3 Pluripotency of spermatogonial stem cell 
It has long been considered a single spermatogonial stem cells can only differentiate into 
sperm-specific manner. But in recent years, studies have shown that the original stem cells 
in vitro can be induced to become pluripotent stem cells. In 2003, Kanatsu-Shinohara first 
began research in this area and found that spermatogonial stem cells isolated from newborn 
mouse could produce embryonic-like stem cells (embryonic stem cell-like, ES-like) cells 
when cultured in vitro. These ES-like cells further cultured in vitro produced ES-like clones, 
which formed teratomas when injected into mice. Subsequently a number of scientific 
researchers discovered that adult mouse spermatogonial stem cells ccould be induced into 
ES-like pluripotent stem cells named multipotent adult germline stem cells (maGSCs). Ko et 
al. (2009) recently made an outstanding contribution by first proving that maGSCs cells was 
indeed changing from spermatogonial stem cells, and differentiated and formed the three 
germ layers both in vitro and in vivo, and the reproductive system could transfer to the next 
generation. Other study also showed that spermatogonial stem cells were very malleable 
and could direct transdifferentiation into other cell types. In 2007, Boulang et al. tried 
spermatogonial stem cell transplantation to the breast, and achieved the breast epithelium in 
vivo. In 2009, U.S. scientists fusioned spermatogonial stem cells and appropriate cells, and 
then grafted the hybrids into the body. Results showed that spermatogonial stem cells could 
differentiate directly into the prostate epithelium, uterine epithelium and skin epithelium in 
newborn mouse. Although the molecular mechanisms of the transition of spermatogonial 
stem cells to pluripotent cells are not clear, scientists successfully induced spermatogonial 
stem cells into pluripotent stem cells in the adult testis, which suggested that 
spermatogonial stem cells will become an important source of pluripotent stem cells in 
medical field.  
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7.2 Primordial germ cell technique 
Primordial germ cells (PGCs) refer to the ancestral cells that can develop into sperm or 
ovum cells. PGCs reside in the recipient’s gonads, migrate and proliferate in the recipient 
embryonic gonads. Because PGCs at different stages of development can serve as transgenic 
recipient cells (Honaramooz etal., 2011), transgenic studies using PGCs as vectors are 
simple, highly effective and will likely gain favor for the production of transgenic animals. 
Development of Mouse Embryonic Primordial Germ Cells was shown in Figure 4. 
 
Fig. 4. Development of Mouse Embryonic Primordial Germ Cells. 
7.2.1 Origin and characteristics of PGCs 
The PGCs originate in the epiblast of the stage X blastoderm. The fusion of an egg and a 
sperm, at fertilization gives rise to a zygote that is totipotent and capable of giving rise to all 
embryonic lineages. In the early embryo, PGCs can be distinguished from the somatic cells 
at 7 days post coitus (d.p.c), because they express an alkaline phosphatase izozyme, tissue 
non-specific alkaline phosphatase (TNAP). 
PGCs are ordinarily identified through morphological characteristics, e.g. large size (12-
20um in diameter), large eccentrically placed nuclei with prominent, often fragmented 
nucleoli. Also some histochemical markers such as periodic acid-schiff (PAS), which stains 
for glycogen, or immunohistochemical markers such as EMA-1 and SSEA-1 (stage-specific 
embryonic antigen 1), which recognize cell-surface carbohydrate epitopes, are used for 
identifing PGCs. 
Recent studies demonstrated that the normal progression of the germ cell lineage during 
gonadogenesis involved a delicate balance of primordial germ cell survival and death 
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factors generated by surrounding somatic cells. This balance operates in a different fashion 
in females and males. The tuning primordial germ cell specification in the wall of the yolk 
sac, migration through the hindgut and dorsal mesentery, and colonization in the urogenital 
ridges involves the temporal and spatial activation of the following signaling pathways. 
Primordial germ cell specification involves bone morphogenetic proteins 2, 4 and 8b, and 
their migration is facilitated by the c-kit receptor-ligand duet. When colonization occurs: (1) 
neuregulin-b ligand is expressed and binds to an ErbB2-ErbB3 receptor tyrosine kinase 
heterodimer on primordial germ cells; (2) Vasa, an ortholog of the Drosophila gene vasa, a 
member of an ATP-dependent RNA helicase of the DEAD (Asp-Glu-Ala-Asp)-box family 
protein is also expressed by primordial germ cells; (3) Bcl-x (cell survival factor) and Bax 
(cell death factor) join forces to modulate the first burst of primordial germ cell apoptosis; 
(4) Cadherins, integrins, and disintegrins bring together primordial germ cells and somatic 
cells to organize testis and ovary. Information on other inducers of primordial cell survival, 
such as teratoma (TER) factor, is beginning to emerge. 
7.2.2 Transgenesis using PGCs 
Several methods of inserting DNA into PGCs are available. Mueller et al. (1999) isolated 
PGCs from pig fetuses, generated hemizygous transgenic cells for a human growth hormone 
(hGH) gene, and obtained chimeric pigs following blastocyst injection of transgenic porcine 
PGCs. Van de Lavoir et al. (2006) targeted chicken PGCs with a GFP gene construct, and 
transplanted the targeted cells into primordial gonads of stage XIII–XV chicken embryos 
that had been incubated for 3 days. A total of eight male chicks were obtained. Once fully 
matured, seven sired transgenic chicks carried and expressed the foreign GFP gene. These 
results indicated that it is feasible to use transgenic or gene targeted PGCs to produce 
transgenic animals, even in large animals. In early study, only retroviral infection of 
germinal crescent PGCs had been successfully produced transgenic chicken. DNA 
complexed with liposomes provided a convenient method both in situ and in vitro. Recently, 
electroporation of germinal crescent or blood PGCs or gonagal tissues was used as 
transfection method. 
8. Gene targeting 
Gene targeting is a technology to specifically modify a particular gene in the chromosome 
through homologous recombination and the integration of extrinsic gene into the specific 
target site. Gene targeting technology overcomes random integration events and, therefore, 
is ideal for the modification and reconstruction of biological genetic materials.  
The advent of pronuclear injection, ES cells, and gene knockout technology led to the 
generation of mice harboring gain-of-function or loss-of-function mutations. 
The integrase family consisted of 28 proteins from bacteria, phage, and yeast that have a 
common invariant His-Arg-Tyr triad. These proteins have the function of DNA recognition, 
synapsis, cleavage strand exchange, and relegation. There are four wildly used site-specific 
recombination system in eukaryotic applications: 1) Cre-loxP from bacteriophage P1, 2) FLP-
FRT from plasmid of Saccharomyces cerevisiae, 3) R-RS from Zygosaccharomyces rouxii, 4) 
Gin-Gix from bacteriophage Mu. The Cre-loxP and FLP-FRT systems have been developed 
as wildly applied tools in Drosophila and mouse genetics. 
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8.1 Cre-loxP system 
Cre recombinase, a P1 phage enzyme belongs to λ Int super-gene family. Cre recombinase 
gene is 1029 bp and codes for a 38kDa protein that is a 343 amino acid monomeric protein. 
The enzyme is λ Int super-gene family. It not only has the catalytic activity, but also is 
similar to restriction enzyme by recognizing specific DNA sequences, which are loxP sites, 
and deleting the gene sequence between the loxP sites. Without the aid of any auxiliary 
factors, the efficiency of the reorganization of DNA by Cre recombinase is 70%. Cre 
recombinase can affect the structure of DNA in a variety of substrates, such as linear, 
circular or supercoiled DNA. It is a site-specific recombination enzyme, can mediate two 
LoxP sites (sequence)-specific recombination, the gene sequence between the LoxP sites are 
deleted or reorganized. 
LoxP (locus of X-over P1) sequence from the P1 phage, has two 13bp inverted repeat 
sequences and an interval of 8bp common form. 8bp interval LoxP sequence also defines 
direction. Cre catalyzes DNA strand exchange in the process of covalent binding to DNA, 
13bp repeat sequence is the reverse by Cre enzyme-binding domain. A model experiment in 
genetics using the Cre-lox system was shown in Figure 5. 
 
Fig. 5. A model experiment in genetics using the Cre-lox system. 
8.2 Cre-LoxP system characteristics 
Cre recombinase mediated recombination between two LoxP sites in the restructuring, 
which is a dynamic, reversible process divided into three cases: 1) if the two LoxP sites 
located in a DNA chain, and in the same direction, Cre recombinase can effectively excise 
the sequence between two LoxP sites; 2) if the two LoxP sites located in a DNA chain, but in 
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the opposite direction, Cre recombinase can lead to two LoxP sites between the sequence 
inversion; 3) if the two LoxP sites are located in two different strands of DNA or 
chromosomes, Cre enzyme can mediate the exchange of two strands of DNA or 
chromosomal translocations. In addition, Cre/LoxP can not only recognize the two 13bp 
inverted repeat sequences and 8bp interval region, but also a 13bp inverted repeat sequence 
of the interval or 8bp able when changes occurred and recombined. Using this feature, 
people can build a LoxP site carrier as needed transformation sequences for specific gene 
mutations or repair, to increase the scope of application of the system. 
8.3 Cre-LoxP and transgenic models 
The Cre / LoxP system is wildly used in transgenic technologies in a loss-of-function model. 
The use of Cre / LoxP system to achieve knockout a particular gene in vivo under certain 
conditions needs two transgenic mice. The first mice commonly are obtained with 
embryonic stem cell technology. In both ends of each gene locus contains a loxP sequence, 
then this sequence inserts into embryonic stem cells by homologous recombination, replaced 
the original genome sequence. After this treatment, the embryonic stem cells are re-
implanted into pseudo-pregnant mouse uterus, to re-develop into a complete embryo, 
eventually becoming a transgenic mouse. In this transgenic mouse, loxP sites are introduced 
into the corresponding gene’s intron, which does not affect the function of the 
corresponding gene, so under normal circumstances, the phenotype of mice is normal. 
Second mice are obtained by using transgenic mice injected oocytes or embryonic stem cell 
technology. In this mice, Cre recombinase is placed in a particular gene under the 
regulation, making its expression in a particular condition. Finally, these two mice were 
mated and produced at the same time. With the offspring of these mice, two genotypes in a 
particular type of cells results in the absence of a specific gene.  
Obviously, in different cells or organs a specific gene knockout depends on the chosen 
promoter. Selecting the appropriate promoter to control the expression of Cre recombinase 
in specific parts of the organism under certain conditions, can be achieved under the 
conditions corresponding to a specific gene knockout. So far, several different promoters 
under different conditions are successfully used to achieve gene knockout. These promoters 
can be cell type-specific, such as lck promoter (thymocytes), alphaA crystallin promoter (eye 
lens), calmodulin-dependent kinase II promoter (hippocampus and neocortex), whey acidic 
protein promoter (mammary gland), aP2 promoter (adipose tissue), AQP2 promoter (kidney 
collecting duct) and sarcoplasmic protein promoter (skeletal muscle), etc. Promoter can also 
be subject to certain exogenous chemicals regulation such as interferon response Mxl 
promoter, Mosey phenol-dependent mutant estrogen promoter and tetracycline regulation 
system. Regulation of exogenous gene knockout can be avoided in the early embryo because 
the abnormal gene function may have side-effects. 
9. Gene silencing mediated by RNA interference 
RNA interference (RNAi) is the silencing of specific gene expression mediated by the 
formation of double-stranded RNA that results in the inhibition of gene expression by 
degrading mRNA. Therefore, RNAi can achieve the spatiotemporality and reversibility of 
gene expression modulation.  
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Gene silencing has been found to be an important methods of regulating gene expression. In 
gene transfer studies, it is easier to insert a foreign gene into an animal genome than to 
remove an existing gene, unless by a knock-out technique. Gene knock-out is complex, 
difficult and irreversible, once the gene knocked out, it cannot be recovered. The 
development of RNA interference (RNAi) technology, through blocking of gene expression 
or cleavage of the expressed mRNA, allows specific, partial and reversible knock-down of 
the desired gene, and can also achieve spatio-temporal regulation of gene expression.  
The introduction of 21 nt small RNA, which is fully or partially complementary to an 
endogenous gene, into animal cells or tissues will interfere with the expression of the 
endogenous gene, or trigger the cleavage of the expressed mRNA. Consequently, RNAi 
impairs gene function or alters an animal trait. For example, Acosta et al. (2005) 
microinjected myostatin small interference RNA (siRNA) into fertilized eggs of zebra fish, 
which resulted in virtually eliminating myostatin mRNA, reducing the inhibitory effect of 
myostatin on muscle growth and creating muscle hypergrowth fish. Such microinjected 
siRNA molecules, although they might be carried over to progenies and remain functional, 
were not integrated into the genome and not inheritable. Dann et al. (2006) microinjected a 
rat fertilized egg with a lentiviral vector that directed expression of a short hairpin RNA 
(shRNA) of the Dazl gene, which is normally expressed by germ cells and is critical for 
fertility. Result showed that Dazl protein was substantially depressed in the testes of pups, 
and the pups were sterile. This RNA interference effect by the transferred gene was 
inherited for at least three generations.  
By using the Cre–loxP system and combining RNA polymerase promoter sequence and 
complementary sequence of the targeted gene, a new method of spatio-temporal RNA 
interference was invented (Ventura et al., 2004; Yu and McMahon, 2006). However, this gene 
targeting based technique is not reversible. Turning the RNAi on and off at will should not 
involve the genomic modification, but may be achieved through the regulation of 
transcription of the RNA interfering gene. Kistner et al. (1996) developed a transcription 
factor (tTA) which was only activated in the presence of tetracycline. Such a transcription 
factor was transferred into the mouse genome and, in the presence of tetracycline, bound 
with the specific promoter, tetracycline response element (TRE), and activated transcription 
of the downstream gene of interest. Dickins et al. (2007) combined the TRE with the RNAi 
sequence, and obtained transgenic mice having the hybrid gene. Using a proper mating 
system, transgenic mice with both the TRE-RNAi and tTA transgenes were prepared. 
Administration of tetracycline to such mice activated the transcription factor tTA, and 
subsequently activated transcription of the RNAi gene, which silenced the expression of the 
target gene (Dickins et al., 2007). Withdrawal of tetracycline terminated the expression of the 
RNAi gene and the interference with the target gene, thus achieving reversible RNA 
interference. Using the reversible RNAi theory to create transgenic animals, so to reversibly 
silence or knock down genes, may help to change reversibly physiological activities of 
animals and even humans. 
10. Zinc-finger nucleases – Gene targeting technique 
Recently the emergence of the zinc finger nuclease (ZFN) technique signified a qualitative 
leap in gene targeting techniques. ZFN is comprised of one DNA binding domain and one 
non-specific endonuclease domain. ZFN can bind and cut DNA at specific sites, introduce 
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double-stranded DNA break at a specific location, transfer extrinsic DNA by induction of 
the endogenous DNA repair procedure, homology-directed repair or non-homology 
terminal junction, and modify the cellular endogenous gene. This technique breaks through 
the limitation of gene targeting efficacy which is enhanced by five orders of magnitude.  
Hence the development of ZFN-mediated gene targeting technology provides molecular 
biologists with the ability to site-specifically modify mammalian genomes, including the 
human genome, via the homology-directed repair of a targeted genomic double-strand 
break (DSB). ZFNs are showing promise as reagents that can create gene-specific DSBs. 
ZFNs are artificial proteins by fusing a specific zinc finger DNA-binding domain with a 
nonspecific endonuclease domain from the FokI restriction enzyme. ZFNs can create specific 
DSBs in vitro. Some studies showed that DSBs stimulate gene targeting or homologous 
recombination in Xenopus oocytes, Drosophila melanogaster, even in plants. In mammalian 
cells, model ZFNs stimulate gene targeting by a factor of several thousand, as observed 
using a green fluorescent protein (GFP) reporter system. In addition, ZFNs have been 
designed to recognize an endogenous gene (IL2RG) and stimulate gene targeting at one 
allele of the endogenous IL2RG locus in 11% of the cells and at both alleles in 6.5% of the cells. 
Mechanism of DSB by ZFNs requires: 1) two different ZFN monomers to bind to their 
adjacent cognate sites on DNA; 2) the Fokl nuclease domains to dimerize to form the active 
catalytic site for the induction of the DSB. 
ZFN-mediated gene transformation has been successfully achieved in different kinds of cells 
from diverse species, for example, frog oocytes, nematodes, zebra fish, mice, rats and 
humans. Through this approach, the endogenous gene modification efficiency reached 
significant high (>10%). 
10.1 Application of ZFN introduction of foreign genes or fragments of target gene 
mutation 
Up to now, there are very few published papers describing the use of ZFNs to stimulate the 
targeting of natural sites in mammalian cells. For instance, two fundamental biological 
processes: DNA recognition by C2H2 zinc-finger proteins and homology-directed repair of 
DNA double-strand breaks were used in Urnov et al. (2005) research. Zinc-finger proteins 
recognizing a unique chromosomal site can be fused to a nuclease domain, and a double-
strand break induced by the resulting zinc-finger nuclease can create specific sequence 
alterations by stimulating homologous recombination between the chromosome and an 
extrachromosomal DNA donor. Result showed that zinc-finger nucleases designed against 
mutation in the IL2Rgamma gene in an X-linked severe combined immune deficiency 
(SCID) yielded more than 18% gene-modified human cells without selection. 
Foley et al. (2009) adapted this technology to create targeted mutations in the zebrafish germ 
line. ZFNs were engineered that recognize sequences in the zebrafish ortholog of the 
vascular endothelial growth factor-2 receptor, kdr (also known as kdra). Co-injection of 
mRNAs encoding these ZFNs into one-cell-stage zebrafish embryos led to mutagenic lesions 
at the target site that were transmitted through the germ line with high frequency. The use 
of engineered ZFNs to introduce heritable mutations into a genome obviates the need for 
embryonic stem cell lines and should be applicable to most animal species for which early-
stage embryos are easily accessible. 
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So far the development of ZFN technology has gradually matured. The technology is based 
on the ZFN specifically identifiable target DNA. Therefore, the future of ZFP study will 
focus on finding more highly specific ZFP, ZFP and the optimal combination, which can 
greatly reduce the workload of experimental design and validation. 
11. Induced pluripotent stem cell technique 
Induced pluripotent stem cells (iPS) are a cell type that the differentiated body cell is 
transfected with several transcriptional factors and is re-programmed as an embryonic-like 
stem cell. Similarly, iPS has the totipotency of self-renew and differentiation like embryonic 
stem cells.  
iPS cells can be used as target cells for transgenes with extrinsic genes through transgenic 
techniques or be genetically modified through gene targeting or gene knock-out. The iPS 
cells can be used as donor cells for somatic cell nuclei and fused with suitable recipient 
somatic cells to produce transgenic animals.  
iPSCs are adult cells that have been genetically reprogrammed to an embryonic stem cell–
like state by being forced to express genes and factors important for maintaining the 
defining properties of embryonic stem cells. Although these cells meet the defining criteria 
for pluripotent stem cells, it is not known if iPSCs and embryonic stem cells differ in 
clinically significant ways. Mouse iPSCs were first reported in 2006, and human iPSCs were 
first reported in late 2007. Mouse iPSCs demonstrate important characteristics of pluripotent 
stem cells, including expressing stem cell markers, forming tumors containing cells from all 
three germ layers, and being able to contribute to many different tissues when injected into 
mouse embryos at a very early stage in development. Human iPSCs also express stem cell 
markers and are capable of generating cells characteristic of all three germ layers. The Figure 
6 addresses each of iPSC steps in detail. 
11.1 Choice of reprogramming factors 
Direct reprogramming was initially performed in mouse fibroblasts through retroviral 
transduction of 24 candidate genes that were all implicated in the establishment and 
maintenance of the pluripotent state. Four transcription factors, Oct4 (Pou5f1), Sox2, c-Myc, 
and Klf4, play important roles in process. 
However, with further research, it found that in certain circumstances, four transcription 
factors Oct4, Sox2, Nanog, Lin28 could be used to reprogramm human fibroblasts into 
iPSCs. Similarly, in rat fibroblasts transformed by renumbering process, we can use Sox1 or 
Sox3 alternative Sox2, Klf4 can also be replaced with Klf2. According to the target cells to 
different levels of gene expression, transcription factor for re-programming can also be 
adjusted, such as neural stem cells (NSCs) themselves high expression of Sox2 and c-Myc, 
only Oct4 can re-compiled NSCs into iPSCs, only Oct4 and Sox2 are enough to induce 
human umbilical cord blood stem cells into iPSCs. In reprogramming human fibroblast to 
iPSCs, no c-Myc factor involved in can also get successful result, indicating that c-Myc is 
not the necessary iPSCs transcription factor of human fibroblasts. This finding has 
important meaning because c-Myc is a transcription factor highly expressed in tumor 
cells, import of exogenous human c-Myc may activate the new iPSCs into tumor cells at 
inappropriate time. 
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Fig. 6. Overview of the iPSC Derivation Process. 
So far, it is difficult to effectively control a variety of transcription factor gene expression 
parameters. Transcription factor genes in a variety of programming over the entire role of 
process, status, and mechanisms are poorly understood. Generally speaking, it seems that 
Oct4 is essential, while the other three main factors are to promote or strengthen the 
effectiveness of Oct4, which can be replaced. 
While the original suite of four factors remains the standard for direct reprogramming, a lot 
of small molecules and additional factors have been reported to enhance the reprogramming 
process and/or functionally replace the role of some of the transcription factors. For 
example: valproic acid, a histone deacetylase inhibitor, enhances reprogramming efficiency 
with four factors (O/S/M/K) in mouse fibroblasts, restores reprogramming efficiency in 
mouse fibroblasts without c-Myc (O/S/K only), permits reprogramming of human 
fibroblasts treated with OCT4 and SOX2, though at extremely low efficiency. Others are: 5-
azacytidine; shRNA against Dnmt1, BIX01294, BayK8644, Wnt3a, siRNA against p53 and 
Utf1 cDNA. 
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11.2 Methods of factor delivery 
Once the transcription factors are selected to transfer to target cells, delivery methods is 
another key to success. From the initial use of retroviral vectors to Lentiviral vector, these 
carriers can ensure the expression pattern of transcription factors in transformation of cells. 
However, this viral vector may change or even increase the potential of cell differentiation. 
For iPSCs safely used in clinical, non-integrated carriers must be taken. The new carrier 
called Cre-recombinant virus can be renumbered 5 cases for Parkinson's disease skin 
fibroblast dimensional cells. This vector has the advantage that you can remove one of the 
transcription factor when iPSCs turn to success. PiggyBac transposon renumbering systems 
are also used. When the piggyBac transposon re-compiled successfully, then transposase 
expression transposon is removed to obtain iPSCs without exogenous viral vectors or gene 
transcription.  
The use of integrating viruses for iPSC induction has represented a major roadblock in  
the pursuit of clinically relevant applications. For HIV-based lentivirus method, it is 
constitutive, transduction of both dividing and nondividing cells, temporal control over 
factor expression. But lower expression levels than integrated form is main disadvantage. 
In short, in order to be more conducive to clinical iPSCs, the carrier of transcription factors 
becomes hot spots in the field of iPSCs research. 
11.3 Choice of cell type 
As the capacity of skin fibroblasts derived easily, and culture conditions similar to ESCs, 
skin fibroblasts can be used as trophoblast cells. But fibroblasts are not the only option, a 
variety of somatic cells, such as stomach, liver, pancreas, blood cells and bone marrow 
stromal cells, neural progenitor cells, and even in the adult division at the end of the angle 
stromal cells have been successfully re-compiled into the iPSC. 
Several factors must be considered in determining the optimal cell type for a given 
application: 1) the ease at which reprogramming factors can be introduced, which varies 
both by cell type and delivery approach; 2) the availability and ease of derivation of the 
given cell type; and 3) the age and source of the cell. 
Although additional research is needed, iPSCs are already useful tools for drug 
development and modeling of diseases, and scientists hope to use them in transplantation 
medicine. Viruses are currently used to introduce the reprogramming factors into adult 
cells, and this process must be carefully controlled and tested before the technique can lead 
to useful treatments for humans. In animal studies, the virus used to introduce the stem cell 
factors sometimes causes cancers. Researchers are currently investigating non-viral delivery 
strategies. In any case, this breakthrough discovery has created a powerful new way to "de-
differentiate" cells whose developmental fates had been previously assumed to be 
determined. In addition, tissues derived from iPSCs will be a nearly identical match to the 
cell donor and thus probably avoid rejection by the immune system. The iPSC strategy 
creates pluripotent stem cells that, together with studies of other types of pluripotent stem 
cells, will help researchers learn how to reprogram cells to repair damaged tissues in the 
human body. 
www.intechopen.com
 
Polymerase Chain Reaction 
 
276 
12. Applications  
Transgenic animals have potentially broad application for the improvement of animal 
production quality, the enhancement of production capacity, the studies of human disease 
models and the production of biomedical materials. 
The benefits of these animals to human welfare can be grouped into the following areas: 
12.1 Agricultural applications 
The application of biotechnology to farm animals has the potential to benefit both humans 
and animals in significant ways. 
a. Breeding: Farmers have always used selective breeding to produce animals that exhibit 
desired traits (e.g., increased milk production, high growth rate). Traditional breeding 
is a time-consuming, difficult task. When technology using molecular biology was 
developed, it became possible to develop traits in animals in a shorter time and with 
more precision. In addition, it offers the farmer an easy way to increase yields.  
Take ES cell technology as an example, chimeric nuclear transfer technology and 
production technology is improving, as ES cells are widely used in animal cloning. 
Proliferation of ES cells derived from donor as the nucleus, produced cloned animals. 
ES cells in germline chimeric, then develop into sperm or eggs to produce offspring. 
Animal cloning technology can produce excellent breeding, combination of genes and 
their high proportion in the population in short time. 
b. Quality: Transgenic cows exist that produce more milk or milk with less lactose or 
cholesterol, pigs and cattle that have more meat on them, and sheep that grow more 
wool. In the past, farmers used growth hormones to spur the development of animals 
but this technique was problematic, especially since residue of the hormones remained 
in the animal product.  
At present the production of transgenic animals in low efficiency is one of the main 
problems. The results of the testing work are carried out at the individual level. Using ES 
cells as a carrier, directed transformation of ES cells, the integration of inserted genes, 
expression level and stability of interested genes can be screened. The work is carried out at 
the cellular level, which is easy to obtain stable cell line with expression of satisfaction, 
accessing to the target gene carrying the transgene for animals. One success story is artificial 
insemination: the use of this technology from 1950s to 1990s in US, increased the average 
milk production per cow over 300%. 
12.2 Medical applications 
a. Xenotransplantation: Transplant organs may soon come from transgenic animals. 
Transgenic pigs may provide the transplant organs needed to alleviate the shortfall. 
Currently, xenotransplantation is hampered by a pig protein that can cause donor rejection 
but research is underway to remove the pig protein and replace it with a human protein.  
For organ and tissue transplantation, which is known as a "species of daughter cells ", 
for the clinical organization, organ transplantation offers great amount of material 
knockout cells. U.S. ACT companies put the nucleus of human skin into bovine oocytes 
without the genetic information, nurturing issued totipotency cell. If they could be 
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successfully used in clinical, in future, many difficult diseases such as Parkinson's 
disease will be cured.  
b. Nutritional supplements and pharmaceuticals: Milk-producing transgenic animals are 
especially useful for medicines. Products such as insulin, growth hormone, and blood 
anti-clotting factors may soon be or have already been obtained from the milk of 
transgenic cows, sheep, or goats. Research is also underway to manufacture milk 
through transgenesis for treatment of debilitating diseases such as phenylketonuria 
(PKU), hereditary emphysema, and cystic fibrosis. 
ES cell culture techniques are used in some special body, then the cost can be a huge 
improvement. For example, some special drugs (interferon, antithrombin, erythropoietin 
and other biological systems agents or genetically modified), in body fluids from animals 
(milk, blood, etc.) or tissue extract achieve the body of the animal drug production factory. 
c. Human gene therapy: A transgenic cow exists that produces a substance to help human 
red cells grow. Human gene therapy involves in adding a normal copy of a gene 
(transgene) to the genome of a person carrying defective copies of the gene. The 
potential for treatments for the 5,000 named genetic diseases is huge and transgenic 
animals could play a role. 
The most current human serious medical diseases are cancer, genetic diseases, including 
birth defects, These diseases are caused by abnormal cell transformation and differentiation, 
such as Lesch, Nyhan. Fully understanding the process of cell differentiation and 
development will be able to cure the diseases. Many scientists have established many mouse 
disease models, and expressed human disease gene in mice for further treatment of human 
disease. For example, U.S. National Institute of Molecular Neurology Laboratory used mice 
ESC to induce neuroepithelial cells, implanted them into the brain, and got a large number of 
small conflicts like cells and glial cells. It can be envisaged to treat multiple sclerosis diseases.   
13. Problems and prospects  
Transgenic animals have potentially broad application for the improvement of animal 
production quality, the enhancement of productivity, the studies of human disease models 
and the production of pharmaceuticals. However, there are many pressing problems that 
need to be resolved for transgenic animal studies.  
a. Dietary and food safety concerns: Food safety of bioengineered products is always a 
significant public topic. For the transgenic animals, some of the foreign gene and its 
promoter sequences from the virus may occur in the recipient animals. Homologous 
recombination or integration may cause the formation of new virus. Foreign gene 
inserted in the chromosome locus may also result in different genetic changes in 
different degrees, causing unintended effects. Transgenic animals may also increase the 
risk of zoonotic disease, and cause human allergic reactions. 
b. Environmental impacts: If transgenic animals are in the external environment and 
mating with wildlife, foreign gene may spread, which results in changing the species 
composition of the original genes, causing confusion in species resources. It may also 
lead to the loss of the wild allele, resulting in a decline in genetic diversity. Once 
released into the environment, transgenic animals can disrupt the ecological balance of 
species, genetic diversity of threatened species. For example, once the transgenic fishes 
are into ponds or rivers and out of control, they may affect the balance of ecology. 
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c. Respect for life and “unnaturalness” of genetic engineering: Ethical concern has also 
been discussed about the “unnaturalness” of genetic engineering and the ways it might 
devalue nature and commercialize life. Here we quoted Strachan Donnelley’s view: 
“Animal biotechnology, inspired by of often genuine and legitimate desires to meet human 
and animal need and interests, must beware that it does not pre-empt ‘nature natural’ in the 
minds and hearts of us human beings and replace it with its own ‘nature contrived’…This 
would be the end of us as seekers after ‘living’ natural norms and ways of being human, and 
given the press of our present technological powers, no doubt the end of nature’s richness 
and goodness itself. This would decidedly be a double moral disaster and irresponsibility.” 
With the fast development of animal gene transfer technology, scientists had well improved 
the efficiency of making transgenic animals as well as the control of the transgene. 
Combination of gene targeting with somatic cell cloning or RNAi techniques had created a 
powerful platform for preparation of transgenic animals. However, cloning was still a 
highly unpredictable laboratory protocol, which existed uncertainty results in the 
experiments. These questions deserved each scientist careful attention.  
14. Conclusion 
Transgenic animal techniques have developed rapidly and provided more and improved 
platforms for the preparation of transgenic animals since their emergence. These techniques 
provide an entirely new pathway for the accurate modulation of genes. In addition, 
transgenic animal research may provide the tools for a series of research hotspots like 
microRNA function and iPS cells. All of these developments will provide new ideas and 
bring forth important changes in fields like medicine, health and livestock improvement. In 
particular, the economic and social benefits from the production of bioreactors, drug 
production, and organ culture for human transplantation will be great. 
In summary, this review has attempted to present a comprehensive comparison of the 
currently available transgenic animal technology. Transgenic animal research involves 
consistent exploration and creation, and searching simple, reliable and efficient transgenic 
techniques is the key for transgenic animals. It is conceivable that the development of more 
simple and novel animal transgenic techniques will lead to more transgenic animals and 
related products that will likely improve our livelihood and wellbeing.      
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